^
    18d
    RTB: Evaluate Safety and the Oncolitic Adenovirus VCN-01 Activity in Patients With Refractory Retinoblastoma (clinicaltrials.gov)
    P=N/A, N=13, Active, not recruiting, Fundació Sant Joan de Déu | Recruiting --> Active, not recruiting | Phase classification: P1 --> PN/A | Trial completion date: Jun 2022 --> Jul 2024 | Trial primary completion date: Jun 2022 --> Jun 2024
    Enrollment closed • Phase classification • Trial completion date • Trial primary completion date • Oncolytic virus
    |
    RB1 (RB Transcriptional Corepressor 1)
    |
    RB1 mutation
    |
    VCN-01
    5ms
    VIRAGE: Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov)
    P2, N=96, Recruiting, Theriva Biologics SL | Phase classification: P2b --> P2
    Phase classification • Metastases
    |
    gemcitabine • albumin-bound paclitaxel • VCN-01
    8ms
    Oncolytic virotherapies for pediatric tumors. (PubMed, Expert Opin Biol Ther)
    We reviewed seven virus types that have been investigated in past or ongoing pediatric tumor clinical trials: adenovirus (AdV-tk, Celyvir, DNX-2401, VCN-01, Ad-TD-nsIL-12), herpes simplex virus (G207, HSV-1716), vaccinia (JX-594), reovirus (pelareorep), poliovirus (PVSRIPO), measles virus (MV-NIS), and Senecavirus A (SVV-001). However, the antitumor effects of OVT remain variable depending on tumor type and viral agent used. Although the widespread adoption of OVT faces many challenges, we are optimistic that OVT will play an important role alongside standard chemotherapy and radiotherapy for the treatment of malignant pediatric solid tumors in the future.
    Review • Journal • Oncolytic virus
    |
    ProstAtak (aglatimagene besadenovec) • Reolysin (pelareorep) • tasadenoturev (DNX-2401) • HSV G207 • MV-NIS • Pexa-Vec (pexastimogene devacirepvec) • SVV-001 • Seprehvir (HSV1716) • VCN-01
    10ms
    Survival outcomes in phase I trial combining VCN-01 and durvalumab (MEDI4736) in subjects with recurrent/metastatic head and neck squamous cell carcinoma refractory to previous immunotherapy treatment (ESMO 2023)
    Conclusions Encouraging survival was observed in patients progressing to anti-PD(L)-1 agents after systemic VCN-01 with Durvalumab. VCN-01-induced upregulation of PD-L1, which correlated with enhanced patient survival.
    Clinical • P1 data • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8)
    |
    Imfinzi (durvalumab) • VCN-01
    2years
    Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors. (PubMed, J Immunother Cancer)
    Treatment with VCN-01 is feasible and has an acceptable safety. Encouraging biological and clinical activity was observed when administered in combination with nab-paclitaxel plus gemcitabine to patients with pancreatic adenocarcinoma.
    Journal • Oncolytic virus
    |
    RB1 (RB Transcriptional Corepressor 1) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • LAG3 (Lymphocyte Activating 3) • IL10 (Interleukin 10)
    |
    gemcitabine • albumin-bound paclitaxel • VCN-01
    2years
    RTB: Evaluate Safety and the Oncolitic Adenovirus VCN-01 Activity in Patients With Refractory Retinoblastoma (clinicaltrials.gov)
    P1, N=13, Recruiting, Fundació Sant Joan de Déu | Trial completion date: Apr 2021 --> Jun 2022 | Trial primary completion date: Sep 2020 --> Jun 2022
    Trial completion date • Trial primary completion date • Oncolytic virus
    |
    RB1 (RB Transcriptional Corepressor 1)
    |
    RB1 mutation
    |
    VCN-01
    2years
    Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P1, N=20, Active, not recruiting, Institut Català d'Oncologia | Recruiting --> Active, not recruiting | Trial completion date: Dec 2021 --> Jan 2023 | Trial primary completion date: Sep 2021 --> Jan 2023
    Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy
    |
    IL6 (Interleukin 6) • IL10 (Interleukin 10)
    |
    Imfinzi (durvalumab) • VCN-01
    2years
    VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects. (PubMed, J Immunother Cancer)
    VCN-01 is an oncolytic adenovirus with direct antitumor effects and stromal disruption capabilities, representing a new therapeutic agent for cancers with dense stroma.
    Clinical Trial,Phase I • Journal
    |
    RB1 (RB Transcriptional Corepressor 1)
    |
    VCN-01
    4years
    RTB: Evaluate Safety and the Oncolitic Adenovirus VCN-01 Activity in Patients With Refractory Retinoblastoma (clinicaltrials.gov)
    P1, N=13, Recruiting, Fundació Sant Joan de Déu | Trial completion date: Nov 2019 --> Apr 2021 | Trial primary completion date: Sep 2019 --> Sep 2020
    Clinical • Trial completion date • Trial primary completion date
    |
    RB1 (RB Transcriptional Corepressor 1)
    |
    RB1 mutation
    |
    VCN-01
    4years
    Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01. (PubMed, Sci Transl Med)
    The treatment caused local vitreous inflammation but no systemic complications. Thus, oncolytic adenoviruses targeting RB1 might provide a tumor-selective and chemotherapy-independent treatment option for retinoblastoma.
    Journal
    |
    RB1 (RB Transcriptional Corepressor 1)
    |
    VCN-01
    over4years
    VCN-01 plus durvalumab in subjects with recurrent/metastatic head & neck squamous cell carcinoma (R/M HNSCC): Phase I clinical trial (ESMO-IO 2019)
    Funding: VCN Biosciences, AstraZeneca. Clinical trial identification: NCT03799744.
    Clinical • P1 data • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8)
    |
    Imfinzi (durvalumab) • VCN-01